{"doi":"10.1056/nejme2407731","title":"Targeting CSF1R in Chronic GVHD — Lessons in Translation","abstract":null,"journal":"New England Journal of Medicine","year":2024,"id":635225,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":520488,"name":"Stefanie Sarantopoulos","orcid":"0000-0003-4551-6687","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Targeting CSF1R in Chronic GVHD — Lessons in Translation","abstract":"Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means of allogeneic hematopoietic stem-cell transplantation (HSCT). After allogeneic HSCT is performed, ongoing loss of T-cell and B-cell immune tolerance occurs as a new immune system develops under constant exposure to foreign host and tumor antigens. Patients with chronic GVHD can have hallmark fibrotic features such as scleroderma and lung fibrosis that are typically refractory to classic immunosuppressants. 1 More details on chronic GVHD can be found in the editorial by Mohty in this issue . . .","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39292932","pmcid":null,"openalex_id":"https://openalex.org/W4402621997","authors":[],"funders":[],"total_grants":0,"fwci":0.779,"citation_percentile":0.69883213,"influential_citations":0,"citation_trend":[{"year":2024,"count":3},{"year":2026,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.nejm.org/doi/pdf/10.1056/NEJMe2407731","host_type":"publisher"},{"url":"https://doi.org/10.1056/nejme2407731","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39292932","host_type":"repository"}],"fields_of_study":["Immune cells in cancer","Cancer, Hypoxia, and Metabolism","Immune Cell Function and Interaction","Medicine"],"mesh_terms":["Animals","Chronic Disease","Disease Models, Animal","Graft vs Host Disease","Humans","Transplantation, Homologous","Multicenter Studies as Topic","Signal Transduction","Randomized Controlled Trials as Topic","Receptor, Macrophage Colony-Stimulating Factor","Receptors, Granulocyte-Macrophage Colony-Stimulating Factor","Clinical Trials, Phase II as Topic","Hematopoietic Stem Cell Transplantation","Mice","Antibodies, Monoclonal, Humanized"],"keywords":["Translation (biology)","Medicine","Intensive care medicine","Biology","Genetics"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:48:27.221327Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}